Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Trends

Report ID: GMI11141
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Trends

Ongoing innovation in the development of targeted therapies, such as complement inhibitors like eculizumab and ravulizumab, has revolutionized PNH treatment. These therapies effectively reduce hemolysis and improve patient outcomes, leading to higher adoption rates, which are anticipated to propel market growth. Moreover, leading pharmaceutical companies are heavily investing in the research and development of new drugs and therapies for PNH, resulting in a robust pipeline of potential treatments that contribute to market growth. For instance, in April 2024, Voydeya (danicopan) was approved in the U.S. as an add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with PNH. This approval aims to broaden treatment availability, complementing existing therapies for PNH and contributing to market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The paroxysmal nocturnal hemoglobinuria treatment market was valued at USD 3.9 billion in 2023 and is expected to grow at 11.2% CAGR during 2024-2032 due to the rising prevalence of PNH.

The complement inhibitors segment in the market generated USD 1.4 billion in 2023 owing to the strong clinical results.

North America paroxysmal nocturnal hemoglobinuria treatment market held 46.6% in 2023 favored by the need for insurance coverage for high-cost drugs.

Amgen Inc., Apellis Pharmaceuticals, Inc., AstraZeneca Plc, Children's National Hospital, F. Hoffmann-La Roche Ltd., Memorial Sloan Kettering Cancer Center, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals Inc., and Teva Pharmaceuticals Industries Ltd. among others.